Trial Profile
Phase II study of brilacidin for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2019
Price :
$35
*
At a glance
- Drugs Brilacidin (Primary) ; Brilacidin (Primary)
- Indications Ulcerative colitis; Ulcerative proctitis; Ulcerative proctosigmoiditis
- Focus Proof of concept; Therapeutic Use
- Sponsors Innovation Pharmaceuticals
- 14 Jan 2019 According to an Innovation Pharmaceuticals media release, in late 2018 the company presented data as a scientific poster at the inaugural IBD Innovate 2018 conference, hosted by the Crohns & Colitis Foundation.
- 20 Sep 2018 Status changed from active, no longer recruiting to completed, according to an Innovation Pharmaceuticals media release.
- 13 Jul 2017 Results from this trial have been presented at the Drug Discovery & Therapy World Congress, according to an Innovation Pharmaceuticals media release.